Demographics and ICU course | Patient A | Patient B |
Age (years) | 50–55 | 50–55 |
Body mass index (kg/m²) | 29.4 | 25.7 |
Rituximab | ||
Indication | Rheumatoid arthritis | Mantle cell lymphoma |
Last infusion (months prior to COVID-19 infection) | 4 | 1 |
Dose (mg) | 1000 | 828.75 |
B cell depletion | Complete | Complete |
Gammaglobulin, baseline (mg/dL) | 140 | 447 |
Further comorbidities | Hypertension | None |
Tertiary care ICU admission | ||
Preceding length of COVID-19 symptoms (days) | 33 | 34 |
Preceding hospital stay (days) | 3 | 15 |
SARS-CoV-2 confirmation by RT-PCR | Yes | Yes |
Mechanical ventilation | Yes | Yes |
PaO2/FiO2 (mm Hg) | 72 | 178 |
SOFA score | 9 | 15 |
APACHE II score | 31 | 39 |
Leucocytes (×1000/µL) | 5.6 | 3.9 |
Lymphocytes (×1000/µL) | 0.2 | 0.7 |
Thrombocytes (×1000/µL) | 95 | 16 |
Erythrocytes (×1000/µL) | 2.7 | 2.7 |
IL-6 (pg/mL) | 641 | 518 |
Ferritin (µg/L) | 6757 | 23 986 |
Tertiary care ICU course | ||
ICU stay (days) | 9 | 25 |
Mechanical ventilation (days) | 6 | 10 |
Renal replacement therapy | None | Intermittent |
SARS-CoV-2 RNA, airway material | Cont. positive | Cont. positive |
SARS-CoV-2 RNA, serum | Cont. positive | Cont. negative |
Anti-SARS-CoV-2-Spike-RBD antibodies | Not detectable | Not detectable |
Complications | Haemorrhage | Urinary tract infection |
PE | ||
SAB | ||
VT | ||
Survival on ICU discharge | Yes | Yes |
APACHE, acute physiology and chronic health evaluation; cont., continuously; ICU, intensive care unit; IL-6, interleukin 6; PE, pulmonary embolism; RBD, receptor binding domaine; RT-PCR, reverse transcription PCR; SAB, subarachnoid haemorrhage; SOFA, sequential organ failure assessment; VT, ventricular tachycardia.